Wang Xi-Sheng, Mei Yun-Qing, Lu Ya-Feng, Cai Jian-Zhi, Ji Qiang, Tang Chu-Zhong, Li Tian-Chang, Hu Da-Yi
Pneumon-cardiovascular Center, Institute of Pneumon-cardiovascular Diseases, Department of Thoracic and Cardiovascular Surgery, Tongji Hospital of Tongji University, Shanghai 200065, China.
Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):101-4.
To investigate the effect of pravastatin on blood lipids and serum high sensitive C-reactive protein (HsCRP) in patients undergoing conventional coronary artery bypass grafting under on-pump bypass (CCABG).
Eighty-one patients underwent CCABG. Among which 40 took orally pravastatin 20 mg once daily to at least 28 days after operation, and 41 were used as control group. The serum levels of total cholesterol (TC), triglyceride (TG), HDL-C cholesterol (HDL-C), LDL-C cholesterol (LDL-C), and HsCRP were monitored before and 24 h, 72 h, 7 days, 10 days, 14 days, and 28 days postoperatively.
In the control group the levels of different blood lipids after operation remarkably decreased after operation compared with those before operation (all P < 0.05), reached the lowest levels 24 h after operation, then gradually increased, however, still lower than those before operation (all P < 0.05), and recovered to the baseline level 28 hours after operation; and the HsCRP level increased 24 h after operation and peaked 72 h after, then gradually decreased, and recovered to the baseline level 28 days after operation. In the pravastatin group the TC level reached its lowest level 24 h after operation, then gradually increased, however, still lower than that before operation, and recovered to the baseline level 28 days after operation; and the TG level reached the lowest level 24 h after operation (P < 0.05), and then gradually increased 3 d after operation (P > 0.05). The TC, TG, and LDL-C levels 7, 10, 14, and 28 d after operation of the pravastatin group were all significantly lower than those of the control group (all P < 0.05). The HsCRP levels at different time points of the pravastatin group were all significantly lower than those of the control group (all P < 0.05).
The use of pravastatin in the early stage of CCABG is safe and can decrease systemic inflammatory reaction.
探讨普伐他汀对在体外循环下行常规冠状动脉旁路移植术（CCABG）患者血脂及血清高敏C反应蛋白（HsCRP）的影响。
81例患者接受CCABG。其中40例术后每日口服普伐他汀20mg，至少服用28天，41例作为对照组。于术前、术后24小时、72小时、7天、10天、14天及28天监测血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）及HsCRP水平。
对照组术后不同血脂水平较术前显著降低（均P<0.05），术后24小时降至最低水平，随后逐渐升高，但仍低于术前（均P<0.05），术后28天恢复至基线水平；HsCRP水平术后24小时升高，72小时达峰值，随后逐渐下降，术后28天恢复至基线水平。普伐他汀组术后24小时TC水平降至最低，随后逐渐升高，但仍低于术前，术后28天恢复至基线水平；TG水平术后24小时降至最低（P<0.05），术后3天逐渐升高（P>0.05）。普伐他汀组术后7天、10天、十四天及28天的TC、TG及LDL-C水平均显著低于对照组（均P<0.05）。普伐他汀组不同时间点的HsCRP水平均显著低于对照组（均P<0.05）。
CCABG早期使用普伐他汀安全，可减轻全身炎症反应。
